Cicada Brood XIV to emerge in NY soon: When to expect them
A brood of cicadas that only emerges every 17 years is set to make its appearance in New York this spring.
The Empire State and at least 13 other states — Georgia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Virginia, West Virginia and nine southern counties in Indiana — will soon be filled with the hum of these periodical insects.
Here's what to know.
Billions of Brood XIV cicadas, which is considered the second largest periodical cicada brood, according to the University of Connecticut, will most likely come out of the ground during the second half of May.
It's one of 15 broods of periodical cicadas that emerge every 13 or 17 years, reported the Cincinnati Enquirer, part of the USA TODAY Network, and they'll emerge when soil temperatures reach 64 degrees. While annual cicadas emerge worldwide each year, periodical cicadas can only be found in the eastern United States, the Enquirer reported.
The last time this brood appeared was in 2008, says Gene Kritsky, founder of Cicada Safari, a group a group that gathers data on the insects, and biology professor at Mount Saint Joseph University in Cincinnati, Ohio.
Brood XIV cicadas will emerge on a small part of Long Island in the coming months as periodical cicadas typically emerge in May and June, according to the New York State Department of Conservation. However, it's unclear what this year's cicada population will look like on Long Island as it's been declining for at least the last two cycles — or 34 years — and the area has experienced some severe droughts, Kritsky says.
Here's a map of the anticipated 2025 Brood XIV cicada emergence created by USA TODAY:
Cicadas, which are often mistaken for locusts, are insects that belong to the hemiptera order, which includes stink bugs, bed bugs, aphids and cicada families, Kritsky said.
The oldest historical record of Brood XIV cicadas is from 1634, when Pilgrims at Plymouth Colony recorded them, according to Kritsky. However, Native Americans knew of them for centuries prior to European contact, he wrote on his website.
There are three different species of 17-year periodical cicadas, Kritsky added: Magicicada septendecim, magicicada cassini and magicicada septendecula. There are some differences among the three species, such as their calls and colors.
Here are some additional facts about cicadas, according to Kritsky:
Only male cicadas sing or make that buzzing noise they're known for and they do so by using sound-producing structures called tymbals, which are located on the side of their abdomens.
Cicadas typically make the most noise during the day and Kritsky has recorded their calls or songs at decibel readings of 102, which is louder than jets flying into an airport.
There are many more male cicadas than females because female cicadas die after mating once while males mate until they can't anymore, then die.
After mating, female cicadas lay eggs in branches on trees, which hatch 6-10 weeks later and the young cicadas head underground, where they feed on grass roots.
Contributing: USA TODAY
Emily Barnes reports on consumer-related issues for the USA TODAY Network's New York Connect Team, focusing on scam and recall-related topics. Follow her on X and Instagram @byemilybarnes. Get in touch at ebarnes@gannett.com.
This article originally appeared on Rochester Democrat and Chronicle: Cicada Brood XIV to emerge in NY soon: When to expect them
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs. ic-dl/giv
Medscape
2 hours ago
- Medscape
Fast Five Quiz: B-Cell Acute Lymphoblastic Leukemia
Though more common in pediatric populations, B-cell acute lymphoblastic leukemia (B-ALL) affects both children and adults, and it has several genetic subtypes that significantly affect prognosis and treatment decisions. Despite advances in treatment protocols, resistance mechanisms remain a significant challenge. However, some genetic subtypes are associated with more favorable prognosis, and the nuances of this disease are evident in the cascading treatment algorithm recommended by the National Comprehensive Cancer Network (NCCN) for pediatric and adult cases. What do you know about B-ALL? Check your knowledge with this quick quiz. The treatment of B-ALL involves a complex and intensive series of steps. In the induction phase, glucocorticoids are typically used to reduce tumor burden by clearing leukemic cells from the bone marrow. However, point mutations in the NR3C1 gene generally cause resistance to glucocorticoid therapy, which can significantly affect prognosis. Mutations in the CREBBP gene also cause resistance to glucocorticoids DHFR , FPGS , and TYMS genes have been shown to generally cause resistance to methotrexate, not glucocorticoids. Learn more about corticosteroids in B-ALL. In risk stratification for B-ALL, the NCCN notes that having a white blood cell count of > 30 x 109/L is considered a high-risk feature. This is consistent with European guidelines. The NCCN also states that age over 35 years is another high-risk feature for B-ALL. ETP phenotype is a high-risk feature for T-cell acute lymphoblastic leukemia rather than the B-ALL subtype. Hyperdiploidy (a molecular subtype of B-ALL with 51-65 chromosomes) is considered standard risk by the NCCN; data have shown better prognosis for pediatric patients with this subtype. Learn more about risk stratification for B-ALL. TKIs are an important component of induction, consolidation, and maintenance treatment for Ph+ B-ALL. They are recommended by the NCCN for use in conjunction with other drugs, such as corticosteroids, blinatumomab, and inotuzumab ozogamicin (depending on treatment phase and disease severity) and as a treatment post-HCT. They recommend continuing TKI therapy for at least 2 years after HCT, although they note that the 'optimal duration' is unknown for this population. A recent review, however, notes that despite their success in patients with Ph+ B-ALL, approximately 25% of cases will develop resistance to TKIs. Given this possibility, the NCCN notes that clinicians should consider prior TKI intolerance, dose used, BCR::ABL1 mutations, and disease-related features when choosing a specific TKI; they specifically recommend bosutinib, dasatinib, imatinib, nilotinib, or ponatinib as options for TKI therapy. Learn more about Ph+ B-ALL treatments. The DUX4-rearranged subtype of B-ALL is considered to have a favorable prognosis in adolescents and young adults, compared with MEF2D-rearranged, CDX2/UBTF, and IDH1/2; these subtypes generally have inferior prognosis in the same populations (although MEF2D-rearranged has intermediate prognosis in adults). Specifically, DUX4-rearranged B-ALL has been associated with 93% event-free survival and overall survival in pediatric patients, and adolescent and young-adult patients also see longer disease-free survival after complete remission is achieved. Learn more about B-ALL genomics. Several genetic subtypes of B-ALL are associated with varying prognoses, and the outcomes differences seen between pediatric and adult patients can be partly explained by the different subtypes expressed by these populations. Further, new therapies have enabled high survival rates among pediatric patients with B-ALL, with long-term survival of up to 90% in this population. Prognosis for B-ALL in adolescents and adults is comparatively poor. For example, a population-based study reported the following declining survival rates with age: 74% for patients 15-19 years old, 59% for patients 20-39 years old, and 43% for those 40-59 years old. However, the researchers explained that these percentages still demonstrate improvements, as survival rates were overall lower in the 1980s and 1990s. Learn more about B-ALL prognosis.
Yahoo
6 hours ago
- Yahoo
Europe prepares to land rover on the Moon for first time
The first European Moon rover is due to land on the lunar surface on Thursday. Named Tenacious, the rover is less than 2ft long and can carry a payload of just over one pound. Built by the European arm of Japanese lunar exploration company Ispace, it will be controlled by ground staff in Luxembourg, who will be able to drive it at up to four inches per second in near real time, using a video camera mounted on its front panel. Once on the Moon, it will deliver an art project called Moonhouse, a 3in-high model of a typical red Swedish cottage, developed by Mikael Genberg, a Swedish artist. The team hopes to place the house in a location where it can be photographed with the Earth in the background. The rover is also carrying a shovel to collect lunar regolith – moon dust – which will be sold to Nasa for $5,000 (£3,685) under an agreement that will make history as the first off-planet sale of resources. It is the second attempt to land on the Moon by Ispace, after the company's first craft crash-landed on the lunar surface in 2020. An investigation later found that a software glitch had led the spacecraft to believe it was on the surface when it was still several miles from landing. Takeshi Hakamada, the founder of Ispace, said: 'Just over two years ago, Ispace became the first private company in the world to attempt a lunar landing. 'While the mission achieved significant results, we lost communication with the lander just before touchdown. 'Since that time, we have drawn on the experience, using it as motivation to move forward with resolve. We are now at the dawn of our next attempt to make history.' The rover is being carried in a lander spacecraft called Resilience which launched in January on a SpaceX Falcon 9 rocket and entered lunar orbit on May 6. It is due to land on the Mare Frigoris region of the northern hemisphere of the near side of the Moon at 19:17 BST. The team is hoping that the area will be flat enough to allow the rover to trundle around, although its sturdy wheels should help it navigate unexpectedly rough terrain. Sophia Casanova, a senior lunar scientist at Ispace, said: 'The mission will be going to a really exciting region on the Moon. We are hoping to encounter a range of really interesting geologic features, and in particular with our Tenacious rover we will be exploring the lunar regolith, which is the soil-like material that covers the lunar surface. 'Understanding the characteristics of this material will help us not only understand the geology of the Moon but also help us understand the design of our future rovers.' She added: 'The Tenacious rover may encounter an array of features that may pose a hazard. Things like steep slopes, highly fluffy or compacted material, or small craters and boulders. However, these features represent really important characteristics for us to evaluate and our rover was designed with these operational conditions in mind.' The lander is also carrying several payloads including a water electrolyser for splitting water into hydrogen and oxygen atoms, as well as experiments looking at food production and space radiation. Kathryn Hadler, the director of the European Space Resources Innovation Centre, said: 'There are many resources of interest on the Moon, we can use the oxygen and metals present on the dust that coats the surface of the Moon, and we are also interested in the water ice that is present in the permanently shadowed reasons. 'This is important because we can use these resources to support human life, we can use it for rocket propellant, and this will allow us to support a future of sustainable space exploration. 'We need to develop the technologies to allow us to use these resources in space. It will allow us to understand how the regolith behaves when it is scooped and handled. And this is critical to develop technology for future space missions.' Ispace has previously said that its goal is to kick off the lunar economy, and it has several more missions planned, including working on two more landers. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
